Skip to content

Matching Glaucoma With Impaired Cognition

Association of Glaucoma Morbidity and Impairment of Topological Perception: a Cohort Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03695224
Acronym
MAGIC
Enrollment
3000
Registered
2018-10-04
Start date
2018-10-08
Completion date
2025-03-31
Last updated
2022-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Morbidity of Primary Open Angle Glaucoma

Keywords

Topological perception, Glaucoma

Brief summary

Glaucoma is the leading cause of irreversible blindness in the world. The current study is designed to find the underlying relationship between impairment of topological perception and incidence of glaucoma.

Detailed description

Glaucoma is currently the leading cause of irreversible blindness in the world. It has been a difficult task for ophthalmologists and researchers to diagnose glaucoma, especially in early stage. At present, glaucoma diagnosis mainly relies on OCT and visual field test, which have relatively low sensitivity and specificity at the early stage of glaucoma. Previous studies mainly focused on ocular manifestation of glaucoma. However, there was evidence that abnormalities of visual pathway also existed in patients with glaucoma, indicating cerebral cognitive defects may also be involved in glaucoma development. Thus, the current study was designed, in which subjects at high-risk of developing glaucoma are separated into two group based on test results of topological perception. After five years' follow-up, morbidity of primary open-angle glaucoma would be compared between groups to see if there was any relationship between impaired cognitive function and incidence of glaucoma.

Interventions

DIAGNOSTIC_TESTTopological perception test

Participants' topological perception are tested with self-designed devices. Participants are asked to respond to the figures shown on the screen, and a final score will appear after they finish all the questions.

Sponsors

Chinese Academy of Sciences
CollaboratorOTHER_GOV
Sun Yat-sen University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Aged between 18-55; 2. Best corrected visual acuity ≥ 0.6, capable of completing routine glaucoma examinations; 3. Spherical equivalent \< 3D; 4. No history of other ocular diseases (except mild cataract), including diabetic retinopathy, age-related macular degeneration, optical neuropathy, eye trauma, strabismus, nystagmus, severe dry eye, ptosis of the eyelid, etc.

Exclusion criteria

1. Unable or unwilling to sign informed consent, or cannot comply with the study protocol 2. Diagnosed with any kind of glaucoma (based on visual field and OCT, etc) or primary angle-closure diseases(primary angle closure suspect and primary angle closure, based on gonioscopy and UBM examination); 3. History of ocular surgeries or laser; 4. Diagnosed with specific neurologic diseases or psychiatric disorders: Parkinson's disease, Alzheimer's disease, anxiety, depression, schizophrenia, etc.(based on scale screening) 5. With severe systemic diseases: diabetes mellitus, hypertension(systolic pressure≥160mmHg or diastolic pressure≥100mmHg ), heart diseases, kidney diseases, rheumatological disorder, digestive diseases, cancer, etc. 6. Pregnancy or lactation

Design outcomes

Primary

MeasureTime frameDescription
Morbidity of primary open-angle glaucomaFrom October 2018 to September 2024Incidence of primary open angle glaucoma in the study subjects

Secondary

MeasureTime frameDescription
Change in biometric parameters of optic nerve and macular regionFrom October 2018 to September 2024Biometric parameters of optic nerve include retinal nerve fiber layer (RNFL) thickness, ganglion cell layer (GCL) thickness, ganglion cell complex (GCC) thickness, etc.
Change in visual fieldFrom October 2018 to September 2024Mean Deviation (MD value)

Countries

China

Contacts

Primary ContactXiulan Zhang
zhangxl2@mail.sysu.edu.cn8613570166308

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026